Ensysce Biosciences, Inc.
ENSC
$0.25
$0.000.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.40% | -38.44% | 41.64% | 40.95% | 24.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -98.28% | 267.01% |
| Total Other Non-Cash Items | 512.43% | -37.39% | -50.27% | -81.23% | -69.52% |
| Change in Net Operating Assets | 278.00% | 221.41% | 101.26% | 165.42% | 10.12% |
| Cash from Operations | -4.05% | 17.52% | 36.64% | 45.17% | 30.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 74.78% | 77.09% | 74.50% | 81.91% | 40.92% |
| Issuance of Common Stock | -10.50% | -10.67% | 69.56% | -58.80% | -54.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -80.30% | -77.16% | -3.89% | -43.99% | 1,581.87% |
| Cash from Financing | -11.57% | -58.25% | 5.30% | -56.64% | 12.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -66.02% | -192.24% | 141.93% | -117.69% | 217.51% |